FDA Grants Priority Review to Amgen ' s Tarlatamab Application for Advanced Small Cell Lung Cancer

Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC1 If Approved, Tarlatamab Would be the First BiTE® Therapy for a Major Solid Tumor FDA Target Action Date is June 12, 2024 THOUSAND OAKS, Calif.,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials